Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Artelo Biosciences ( (ARTL) ) has provided an announcement.
On October 26, 2025, Artelo Biosciences announced the appointment of Mark Spring as the new Chief Financial Officer, effective November 1, 2025, succeeding Gregory Gorgas. Spring’s extensive experience in financial roles across various biotech companies is expected to enhance Artelo’s financial operations. Additionally, the company amended the employment agreement with Gorgas to align his severance benefits with market practices, reflecting a commitment to governance and compliance.
The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Artelo Biosciences operates in the biotechnology industry, focusing on the development of therapeutics.
Average Trading Volume: 110,582
Technical Sentiment Signal: Sell
Current Market Cap: $3.87M
See more data about ARTL stock on TipRanks’ Stock Analysis page.